NCT07240402

Brief Summary

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Nov 2025

Shorter than P25 for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 16, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

November 17, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 20, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

November 20, 2025

Status Verified

November 1, 2025

Enrollment Period

2 months

First QC Date

November 16, 2025

Last Update Submit

November 16, 2025

Conditions

Keywords

Adductor Canal Block

Outcome Measures

Primary Outcomes (1)

  • Primary outcome:

    • Time to first rescue analgesia .

    24 hours postoperatively.

Study Arms (3)

Group D

EXPERIMENTAL

Patients will receive ACB using 20 ml of bupivacaine 0.25%+ 0.5 µg/kg dexmedetomidine.

Drug: Adductor Canal Block (ACB) Only

Group M

EXPERIMENTAL

Patients will receive ACB using 20 ml of bupivacaine 0.25% +0.1 mg/kg morphine.

Drug: Adductor Canal Block (ACB) Only

Group C

EXPERIMENTAL

Patients will receive ACB using 20 ml of bupivacaine 0.25% alone as a control group.

Drug: Adductor Canal Block (ACB) Only

Interventions

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome: • Time to first rescue analgesia . Secondary outcomes: * Total opioid consumption in 24 hours postoperatively. * Degree of pain using visual analogue scale (VAS). * Degree of patient satisfaction. * Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)

Also known as: adductor canal block
Group CGroup DGroup M

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Body mass index (BMI) of 20-35 kg/m2.
  • Undergoing knee surgeries under spinal anesthesia.

You may not qualify if:

  • Any known allergy or contraindication to local anesthetic.
  • History of substance abuse.
  • Decompansated cardiac, pulmonary, hepatic, renal disease.
  • Obese patients with BMI\>35kg/m2.
  • Pregnant and lactating mothers.
  • Coagulopathies.
  • Local skin infections at the site of injection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Single Person

Intervention Hierarchy (Ancestors)

Marital StatusFamily CharacteristicsDemographyPopulation CharacteristicsSocioeconomic Factors

Central Study Contacts

Ashraf Abd El-Nasser Abd El-Hamid kamel El Rewany Anesthesia KafrElsheikh University Faculty of Medicine Anesthesia, Surg, MBBCH

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ashraf Elrewany

Study Record Dates

First Submitted

November 16, 2025

First Posted

November 20, 2025

Study Start

November 17, 2025

Primary Completion

January 1, 2026

Study Completion

February 1, 2026

Last Updated

November 20, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share